
    
      To evaluate clinical and laboratory safety of CG 8020 and CG 2505 and to evaluate the
      efficacy of CG 8020 and CG 2505 as measured by clinical benefit response, progression-free
      survival, survival and CA 19-9 serum marker levels in chemotherapy naive or experienced
      patients with nonresectable or metastatic adenocarcinoma of the pancreas
    
  